近日，2024美国癌症研究协会（AACR）年会在美国圣地亚哥当地时间4月10日圆满落幕，集萃药康在本次会议上展示了7张海报，引发了与会者的热烈讨论。

集萃药康展示的海报内容涵盖免疫重建小鼠模型、Enhertu耐药肿瘤模型、治疗性抗体的临床前评估、HER2靶向药物、IL-12临床前药物研发、人源化抗体领域小鼠模型、临床前PD-1耐药模型这7项研究成果：

01 Preclinical PD-1 Resistance Models: Crucial Tools for Unveiling PD-1 Resistance Mechanisms and Advancing Novel Treatment Strategies

02 NeoMab™: A Novel Platform for Fully Human Therapeutic Antibody Development

03 Patient-derived xenograft (PDX) models with differential HER2 expression for preclinical evaluation of HER2-targeted therapies

04 Development of a Novel Murine Model, NCG-M/hIL15, for Enhanced Post-HSC Transplantation Immunoreconstruction

05 Development and Application of the NCG-hIL2 Mouse Model: A Humanized Platform for Enhanced NK Cell Evaluation in ADCC Efficacy Testing

06 BALB/c-hIL12RB1/hIL12RB2: A Robust Model for Preclinical Research in Human IL-12 Therapy

07 Breaking Through ADCs Resistance: Constructing Preclinical Enhertu-induced Resistant Model

您可点击下方链接下载集萃药康AACR 2024海报：https://en.gempharmatech.com/content/details100032_5210253.html